{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:48:15Z","timestamp":1777909695285,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2013,1,5]],"date-time":"2013-01-05T00:00:00Z","timestamp":1357344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2013,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the efficacy of cyclosporine 0.05% (CsA) eye drops in patients with Stevens Johnson syndrome (SJS) who had chronic dry eye.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Prospective noncomparative interventional case series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Thirty cases of SJS patients who developed dry eye defined by symptoms and signs, including the Schirmer I test, the fluorescein clearance test (FCT), and corneal staining (fluorescein and Rose Bengal staining) were treated with CsA 0.05% eye drops twice daily for 6 months. Dry eye symptoms, eye injection, tear break up time (TBUT), and corneal staining were evaluated before and after the treatment at 0, 2, 4, and 6 months. The Shirmer I test and FCT were evaluated at 0 and 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seventeen patients (56.67%) completed the study. Eight patients (26.67%) withdrew from the study as a result of intolerable side effects of CsA, which included pain, redness, and eyelid swelling. Five cases were lost in follow up. All 17 cases demonstrated significant improvement in dry eye symptoms, conjunctival injection, corneal staining, Schirmer I test, and FCT (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>CsA 0.05% eye drops might be beneficial in the treatment of chronic dry eye associated with SJS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2012.0009","type":"journal-article","created":{"date-parts":[[2013,1,5]],"date-time":"2013-01-05T10:24:15Z","timestamp":1357381455000},"page":"372-377","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy of Cyclosporine 0.05% Eye Drops in Stevens Johnson Syndrome with Chronic Dry Eye"],"prefix":"10.1177","volume":"29","author":[{"given":"Pinnita","family":"Prabhasawat","sequence":"first","affiliation":[{"name":"Mahidol University","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nattaporn","family":"Tesavibul","sequence":"additional","affiliation":[{"name":"Mahidol University","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chulavech","family":"Karnchanachetanee","sequence":"additional","affiliation":[{"name":"Mahidol University","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirilux","family":"Kasemson","sequence":"additional","affiliation":[{"name":"Mahidol University","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,1,5]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.1999.00342.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.17796\/jcpd.27.1.r476g4640244t45g"},{"key":"e_1_3_2_4_2","first-page":"283","article-title":"Ophthalmic complications and management of Stevens-Johnson syndrome at a tertiary eye care centre in south India","volume":"50","author":"Kompella V.B.","year":"2002","unstructured":"Kompella V.B., , Sangwan V.S., , Bansal A.K., , Garg P., , Aasuri M.K., , Rao G.N. Ophthalmic complications and management of Stevens-Johnson syndrome at a tertiary eye care centre in south India. Indian J. Ophthalmol., 50:283\u2013286. 2002.","journal-title":"Indian J. Ophthalmol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000027505"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(89)80736-X"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.12.048"},{"key":"e_1_3_2_8_2","first-page":"157","article-title":"Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"145","author":"Gueudry J.","year":"2009","unstructured":"Gueudry J., , Roujeau J.C., , Binaghi M., , Soubrane G., , Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch. Dermatol., 145:157\u2013162. 2009.","journal-title":"Arch. Dermatol."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.109124"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(88)33165-9"},{"key":"e_1_3_2_11_2","first-page":"299","article-title":"Conjunctival goblet cell density in normal subjects and in dry eye syndromes","volume":"14","author":"Ralph R.A.","year":"1975","unstructured":"Ralph R.A. Conjunctival goblet cell density in normal subjects and in dry eye syndromes. Invest. Ophthalmol., 14:299\u2013302. 1975.","journal-title":"Invest. Ophthalmol."},{"key":"e_1_3_2_12_2","first-page":"576","article-title":"Parasympathetic innervation of the rat cornea","volume":"36","author":"Marfurt C.F.","year":"1995","unstructured":"Marfurt C.F., , Jones M.A. Parasympathetic innervation of the rat cornea. Invest. Ophthalmol. Vis. Sci., 36,suppl:576. 1995.","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.08.040"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.09.017"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70273-2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0091"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)00176-1"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0215-0"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02697322"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1014"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1602485"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00035-X"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2009.02090.x"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32833a8c15"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2009.02.002"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.08.102"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2008-15105"},{"key":"e_1_3_2_28_2","first-page":"221","article-title":"Report of the National Eye Institute\/Industry workshop on Clinical Trials in Dry Eyes","volume":"21","author":"Lemp M.A.","year":"1995","unstructured":"Lemp M.A. Report of the National Eye Institute\/Industry workshop on Clinical Trials in Dry Eyes. Clao. J., 21:221\u2013232. 1995.","journal-title":"Clao. J."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00192-2"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.11.1489"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.3.330"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.127738"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.05.013"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2012.0009","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2012.0009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2012.0009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:37:45Z","timestamp":1777646265000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2012.0009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,4,1]]}},"alternative-id":["10.1089\/jop.2012.0009"],"URL":"https:\/\/doi.org\/10.1089\/jop.2012.0009","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,5]]}}}